Development of liposomal formulations: From concept to clinical investigations

Abstract Liposome is one of the most successful drug delivery systems applying nanotechnology to potentiate the therapeutic efficacy and reduce toxicities of conventional medicines. Since the first doxorubicin-loaded liposome reached the market, numerous researches have been carried out to develop new liposomal formulations over the past decade and have given birth to a series of commercial products. Therapeutic agents, most of which are anti-cancer drugs, are encapsulated in the aqueous core or lipid bilayers of liposomes to improve their delivery to the targeted tissue. There are several liposomal formulations, such as EndoTAG-1 (paclitaxel-loaded cationic liposomes), Lipoplatin (cisplatin-loaded long circulating liposomes) and Stimuvax (a cancer vaccine), showing promising therapeutic value in clinical studies. Besides, new designs including environmentally sensitive liposomes, liposomal drug combinations and liposomal vaccines are now tested in clinical trials.

[1]  J. Kolitz,et al.  First-in-man study of CPX-351: a liposomal carrier containing cytarabine and daunorubicin in a fixed 5:1 molar ratio for the treatment of relapsed and refractory acute myeloid leukemia. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[2]  H. Kantarjian,et al.  Liposomal vincristine in relapsed non-Hodgkin's lymphomas: early results of an ongoing phase II trial. , 2000, Annals of oncology : official journal of the European Society for Medical Oncology.

[3]  S. Libutti,et al.  Pulsed-High Intensity Focused Ultrasound and Low Temperature–Sensitive Liposomes for Enhanced Targeted Drug Delivery and Antitumor Effect , 2007, Clinical Cancer Research.

[4]  M. Yen,et al.  Pegylated liposomal doxorubicin (Lipo-Dox) for platinum-resistant or refractory epithelial ovarian carcinoma: a Taiwanese gynecologic oncology group study with long-term follow-up. , 2006, Gynecologic oncology.

[5]  K. Edwards,et al.  Optimization and characterization of a sphingomyelin/cholesterol liposome formulation of vinorelbine with promising antitumor activity. , 2005, Journal of pharmaceutical sciences.

[6]  T. Boulikas,et al.  Lipoplatin Formulation Review Article , 2011, Journal of drug delivery.

[7]  G. Gaedicke,et al.  Comparison of immunogenicity and tolerability of a virosome-adjuvanted and a split influenza vaccine in children , 2004, The Pediatric infectious disease journal.

[8]  S. Boorjian,et al.  Phase 1/2 Clinical Trial of Interferon α2b and Weekly Liposome-encapsulated All-trans Retinoic Acid in Patients With Advanced Renal Cell Carcinoma , 2007 .

[9]  M. Yeh,et al.  Clinical development of liposome-based drugs: formulation, characterization, and therapeutic efficacy , 2011, International journal of nanomedicine.

[10]  G. Weinstein,et al.  A Phase I Study of SPI-077 (Stealth® Liposomal Cisplatin) Concurrent with Radiation Therapy for Locally Advanced Head and Neck Cancer , 2002, Investigational New Drugs.

[11]  Janos Szebeni,et al.  Complement activation-related pseudoallergy: a new class of drug-induced acute immune toxicity. , 2005, Toxicology.

[12]  E. Riley,et al.  Single-dose, extended-release epidural morphine (DepoDur) compared to conventional epidural morphine for post-cesarean pain. , 2008, Anesthesia and analgesia.

[13]  J. Kattan,et al.  A phase II study of lipoplatin (liposomal cisplatin)/vinorelbine combination in HER-2/neu-negative metastatic breast cancer. , 2011, Clinical breast cancer.

[14]  G. Stathopoulos,et al.  Comparison of liposomal cisplatin versus cisplatin in non-squamous cell non-small-cell lung cancer , 2011, Cancer Chemotherapy and Pharmacology.

[15]  A. Anagnostopoulos,et al.  The use of liposomal daunorubicin (DaunoXome) in acute myeloid leukemia , 2005, Leukemia & lymphoma.

[16]  Costas Demetzos,et al.  New chimeric advanced Drug Delivery nano Systems (chi-aDDnSs) as doxorubicin carriers. , 2010, International journal of pharmaceutics.

[17]  E. Riley,et al.  Single-Dose, Extended-Release Epidural Morphine (DepoDur™) Compared to Conventional Epidural Morphine for Post-Cesarean Pain , 2007 .

[18]  F. Giles,et al.  OSI-211, a novel liposomal topoisomerase I inhibitor, is active in SCID mouse models of human AML and ALL. , 2003, Leukemia research.

[19]  W. Hong,et al.  Phase II study of a liposome-entrapped cisplatin analog (L-NDDP) administered intrapleurally and pathologic response rates in patients with malignant pleural mesothelioma. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[20]  C. Rodríguez-Antona,et al.  Pharmacogenomics of paclitaxel. , 2010, Pharmacogenomics.

[21]  David M. Brown,et al.  Lucentis® using Visudyne® study: determining the threshold-dose fluence of verteporfin photodynamic therapy combined with intravitreal ranibizumab for exudative macular degeneration , 2010, Clinical ophthalmology.

[22]  C. Herzog,et al.  Eleven years of Inflexal V-a virosomal adjuvanted influenza vaccine. , 2009, Vaccine.

[23]  D. Lacombe,et al.  Phase II study of OSI-211 (liposomal lurtotecan) in patients with metastatic or loco-regional recurrent squamous cell carcinoma of the head and neck. An EORTC New Drug Development Group study. , 2004, European journal of cancer.

[24]  G. Batist,et al.  A multicenter, phase II study of CPX-1 liposome injection in patients (pts) with advanced colorectal cancer (CRC) , 2008 .

[25]  M. Dewhirst,et al.  Comparative effects of thermosensitive doxorubicin-containing liposomes and hyperthermia in human and murine tumours , 2010, International journal of hyperthermia : the official journal of European Society for Hyperthermic Oncology, North American Hyperthermia Group.

[26]  Jin-Hwang Liu,et al.  A Dose-Escalating Pilot Study of Sterically Stabilized, Pegylated Liposomal Doxorubicin (Lipo-Dox®) in Patients with Metastatic Breast Cancer , 2003, Cancer investigation.

[27]  F. Muggia,et al.  Pegylated liposomal doxorubicin HCL (PLD; Caelyx/Doxil): experience with long-term maintenance in responding patients with recurrent epithelial ovarian cancer. , 2006, Annals of oncology : official journal of the European Society for Medical Oncology.

[28]  M. Dellian,et al.  Vascular targeting by EndoTAG™‐1 enhances therapeutic efficacy of conventional chemotherapy in lung and pancreatic cancer , 2010, International journal of cancer.

[29]  D. V. Hoff,et al.  A Phase 2 trial of the liposomal DACH platinum L-NDDP in patients with therapy-refractory advanced colorectal cancer , 2006, Cancer Chemotherapy and Pharmacology.

[30]  L. Dupont,et al.  Pharmacokinetic and Pharmacodynamic Evaluation of Liposomal Amikacin for Inhalation in Cystic Fibrosis Patients with Chronic Pseudomonal Infection , 2009, Antimicrobial Agents and Chemotherapy.

[31]  F. Dosio,et al.  Stealth liposomes: review of the basic science, rationale, and clinical applications, existing and potential , 2006, International journal of nanomedicine.

[32]  Keunchil Park,et al.  INSPIRE: A phase III study of the BLP25 liposome vaccine (L-BLP25) in Asian patients with unresectable stage III non-small cell lung cancer , 2011, BMC Cancer.

[33]  D. Needham,et al.  Lysolipid incorporation in dipalmitoylphosphatidylcholine bilayer membranes enhances the ion permeability and drug release rates at the membrane phase transition. , 2005, Biochimica et biophysica acta.

[34]  G. Hortobagyi,et al.  Phase I study of liposomal annamycin , 2000, Cancer Chemotherapy and Pharmacology.

[35]  J. Wilschut.  Influenza vaccines: the virosome concept. , 2009, Immunology letters.

[36]  V. Usonis,et al.  Antibody titres after primary and booster vaccination of infants and young children with a virosomal hepatitis A vaccine (Epaxal). , 2003, Vaccine.

[37]  H. Maeda,et al.  Polymeric drugs for efficient tumor-targeted drug delivery based on EPR-effect. , 2009, European journal of pharmaceutics and biopharmaceutics : official journal of Arbeitsgemeinschaft fur Pharmazeutische Verfahrenstechnik e.V.

[38]  S. Yusuf,et al.  Anthracycline-induced cardiotoxicity and the cardiac-sparing effect of liposomal formulation , 2007, International journal of nanomedicine.

[39]  L. Gianni,et al.  Lipoplatin Treatment in Lung and Breast Cancer , 2010, Chemotherapy research and practice.

[40]  J. V. Von Roenn,et al.  Randomized phase III trial of liposomal daunorubicin versus doxorubicin, bleomycin, and vincristine in AIDS-related Kaposi's sarcoma. , 1996, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[41]  Mandip Singh,et al.  Lipophilic drug derivatives in liposomes , 1998 .

[42]  P. Ellis,et al.  Updated survival analysis in patients with stage IIIB or IV non-small-cell lung cancer receiving BLP25 liposome vaccine (L-BLP25): phase IIB randomized, multicenter, open-label trial , 2011, Journal of Cancer Research and Clinical Oncology.

[43]  Y. Tseng,et al.  Phase I and pharmacokinetic study of a stable, polyethylene‐glycolated liposomal doxorubicin in patients with solid tumors , 2001, Cancer.

[44]  R. Vile,et al.  Phase I-II study of pegylated liposomal cisplatin (SPI-077) in patients with inoperable head and neck cancer. , 2001, Annals of oncology : official journal of the European Society for Medical Oncology.

[45]  Verteporfin Roundtable Participants.  GUIDELINES FOR USING VERTEPORFIN (VISUDYNE®) IN PHOTODYNAMIC THERAPY TO TREAT CHOROIDAL NEOVASCULARIZATION DUE TO AGE-RELATED MACULAR DEGENERATION AND OTHER CAUSES , 2002, Retina.

[46]  H. Prentice,et al.  Liposomal amphotericin B (AmBisome): safety data from a phase II/III clinical trial. , 1991, The Journal of antimicrobial chemotherapy.

[47]  M. Newman,et al.  Comparative pharmacokinetics, tissue distribution, and therapeutic effectiveness of cisplatin encapsulated in long-circulating, pegylated liposomes (SPI-077) in tumor-bearing mice , 1999, Cancer Chemotherapy and Pharmacology.

[48]  W. Gradishar,et al.  Albumin-bound paclitaxel: a next-generation taxane , 2006, Expert opinion on pharmacotherapy.

[49]  Ulrich Beyer,et al.  Liposomal encapsulated anti-cancer drugs. , 2005, Anti-cancer drugs.

[50]  P. Ellis,et al.  A multicenter open-label study to assess the safety of a new formulation of BLP25 liposome vaccine in patients with unresectable stage III non-small-cell lung cancer. , 2010, Clinical lung cancer.

[51]  Y. Barenholz.  Doxil®--the first FDA-approved nano-drug: lessons learned. , 2012, Journal of controlled release : official journal of the Controlled Release Society.

[52]  L. Gianni,et al.  Anthracyclines: Molecular Advances and Pharmacologic Developments in Antitumor Activity and Cardiotoxicity , 2004, Pharmacological Reviews.

[53]  S. Phuphanich,et al.  A pharmacokinetic study of intra-CSF administered encapsulated cytarabine (DepoCyt®) for the treatment of neoplastic meningitis in patients with leukemia, lymphoma, or solid tumors as part of a phase III study , 2006, Journal of Neuro-Oncology.

[54]  P. Keegan,et al.  FDA drug approval summary: pegaspargase (oncaspar) for the first-line treatment of children with acute lymphoblastic leukemia (ALL). , 2007, The oncologist.

[55]  C. Hartrick,et al.  Extended-release epidural morphine (DepoDur™): review and safety analysis , 2008, Expert review of neurotherapeutics.

[56]  M. Büchert,et al.  Vascular and pharmacokinetic effects of EndoTAG-1 in patients with advanced cancer and liver metastasis. , 2012, Annals of oncology : official journal of the European Society for Medical Oncology.

[57]  R. Gascoyne,et al.  Vincristine sulfate liposomes injection (Marqibo) in heavily pretreated patients with refractory aggressive non‐Hodgkin lymphoma , 2009, Cancer.

[58]  A. Tulpule,et al.  Improving the therapeutic index of anthracycline chemotherapy: focus on liposomal doxorubicin (Myocet). , 2009, Breast.

[59]  S. Rayala,et al.  Nanomedicine: towards development of patient-friendly drug-delivery systems for oncological applications , 2012, International journal of nanomedicine.

[60]  C. Butts,et al.  Vaccination with BLP25 liposome vaccine to treat non-small cell lung and prostate cancers , 2005, Expert review of vaccines.

[61]  Maurizio Chiriva-Internati,et al.  Nanotechnology and human health: risks and benefits , 2010, Journal of applied toxicology : JAT.

[62]  T. Boulikas,et al.  Pharmacokinetics and adverse reactions of a new liposomal cisplatin (Lipoplatin): phase I study. , 2005, Oncology reports.

[63]  Gert Storm,et al.  Polymeric Micelles in Anticancer Therapy: Targeting, Imaging and Triggered Release , 2010, Pharmaceutical Research.

[64]  Lyndsay Harris,et al.  Liposome‐encapsulated doxorubicin compared with conventional doxorubicin in a randomized multicenter trial as first‐line therapy of metastatic breast carcinoma , 2002, Cancer.

[65]  N. Bressler,et al.  Photodynamic therapy with verteporfin (Visudyne): impact on ophthalmology and visual sciences. , 2000, Investigative ophthalmology & visual science.

[66]  Y. Barenholz,et al.  Enhancement of adriamycin delivery to liver metastatic cells with increased tumoricidal effect using liposomes as drug carriers. , 1983, Cancer research.

[67]  L. Galluzzi,et al.  Molecular mechanisms of cisplatin resistance , 2012, Oncogene.

[68]  P. Bovier.  Epaxal®: a virosomal vaccine to prevent hepatitis A infection , 2008, Expert review of vaccines.

[69]  M. Bally,et al.  Characterization of cationic liposome formulations designed to exhibit extended plasma residence times and tumor vasculature targeting properties. , 2010, Journal of pharmaceutical sciences.

[70]  G. Hortobagyi,et al.  Phase II study of liposomal annamycin in the treatment of doxorubicin-resistant breast cancer , 2002, Cancer Chemotherapy and Pharmacology.

[71]  M. Fishman,et al.  Pharmacokinetic/Pharmacodynamic Modeling and Simulation of Neutropenia during Phase I Development of Liposome-Entrapped Paclitaxel , 2008, Clinical Cancer Research.

[72]  A. Santoro,et al.  Reduced cardiotoxicity and comparable efficacy in a phase III trial of pegylated liposomal doxorubicin HCl (CAELYX/Doxil) versus conventional doxorubicin for first-line treatment of metastatic breast cancer. , 2004, Annals of oncology : official journal of the European Society for Medical Oncology.

[73]  Zhili Li,et al.  Characterization of nebulized liposomal amikacin (Arikace) as a function of droplet size. , 2008, Journal of aerosol medicine and pulmonary drug delivery.

[74]  Lawrence Mayer,et al.  In vivo maintenance of synergistic cytarabine:daunorubicin ratios greatly enhances therapeutic efficacy. , 2009, Leukemia research.

[75]  J. Zhang,et al.  Development and characterization of a novel Cremophor EL free liposome-based paclitaxel (LEP-ETU) formulation. , 2005, European journal of pharmaceutics and biopharmaceutics : official journal of Arbeitsgemeinschaft fur Pharmazeutische Verfahrenstechnik e.V.